ClinicalTrials.gg
Sign In
Drug

Lusutrombopag clinical trials

Also written S-888711 and MULPLETA®.

studies test it
8
open now
3
in phase 3
1
first study started
2009

How each study uses lusutrombopag is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lusutrombopag studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 Jul 2018 · MULPLETA · NDA 210923 (FDA, Drugs@FDA)
European Union
18 Feb 2019 · Mulpleo (previously Lusutrombopag Shionogi) · EMEA/H/C/004720 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lusutrombopag
5

Brand

MULPLETA®
3

Development codes

S-888711
5

Studies by the year they started

8 studies that test it; most in 2024 (3)

Studies that test lusutrombopag, by start year
YearStudies
20091
20102
20151
20243
20261

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Purpura, Thrombocytopenic, Idiopathic
3
Thrombocytopenia
2
Anemia, Aplastic
1

Who runs them

Industry 4 · Other 4

Shionogi (4) · Institute of Hematology & Blood Diseases Hospital, China (1) · Peking Union Medical College Hospital (1) · The General Hospital of Western Theater Command (1) · Anhui Provincial Hospital (1)

Often tested with

Tested in the same studies.

Recombinant human thrombopoietin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test lusutrombopag.

Studies

Open first, then newest update. How each study uses lusutrombopag is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

Codes

What other systems call lusutrombopag · ClinicalTrials.gg INT000542

  • MeSH (NLM) C000611387lusutrombopagConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 6LL5JFU42FLUSUTROMBOPAGConfirmed FDA, NLM, Wikidata
  • RxNorm 2054984One source FDA
  • Wikidata Q27265116lusutrombopagConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C166948LusutrombopagOne source FDA
  • DrugBank DB13125One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.